Evidence-Based Interventional Medical Devices for Healthy Longevity

A modality worth more attention in the healthy longevity conversation

The topic of longevity interventions is now mainstream: therapeutic approaches such as

rapamycin, senolytics, GLP-1 receptor agonists, and epigenetic reprogramming;

diagnostic devices such as biological clocks, multiomic biomarkers, and wearables; diet

modifications such as supplements, fasting, and plant-based, low-carbohydrate,

high-protein diets; exercise regimes such as resistance and high-intensity interval

training.

Interventional medical devices — hardware that does something measurable to the

body, to modulate inflammation, rebuild muscle, reset the brain's plasticity, or mimic the

physiological benefits of vigorous exercise — seem relatively underrepresented in the

longevity conversation. Yet such devices may be FDA-cleared, accessible now (or

sooner than most investigational therapeutic approaches), safer than most compounds

introduced into the body, and have more supportive clinical evidence than some

approaches that get considerably more attention.

A scan of major longevity conference programs, venture funding databases, and the

leading academic reviews finds that interventional medical devices rarely warrant a

named category (see note 1).

A note on evidence and regulatory status: several of the devices discussed below hold

clearance or approval for a specific disease indication — rheumatoid arthritis,

depression, wound healing — rather than for aging or healthspan. Their inclusion rests

on the mechanistic overlap between their mode of action and the biology of aging: a device that durably resets the inflammatory setpoint engages the same inflammaging

pathways that accumulate with age; one that rebuilds muscle strength at low

mechanical load directly addresses the sarcopenia that drives frailty. That gap between

an approved beachhead indication and a demonstrated healthspan benefit is real, it is

noted for each device, and closing it is part of the regulatory and clinical work discussed

in the Meaning for Stakeholders section.

Here follows an illustrative, non-exhaustive list of interventional medical devices for

healthy longevity, in rough order of the strength of the evidence. Some are already in

longevity clinics, wellness resorts, or physical therapy clinics; others could be. Some are

as accessible as a gym membership or a home installation. And, the evidence for some

may be surprisingly more extensive, and more directly relevant to aging biology, than

may be generally recognized.

THE BEST EVIDENCED

HARDWARE WITH A CLINICAL TRACK RECORD

1. IMPLANTABLE VAGUS NERVE STIMULATION

RESETTING THE INFLAMMATION SWITCH

The vagus nerve runs from the brainstem down through the chest and abdomen,

innervating the heart, lungs, and gut. Among its many functions, it serves as what

Feinstein Institute neurologist Kevin Tracey has called the "on/off switch" for the body's

production of pro-inflammatory cytokines — particularly TNF-alpha. That insight gave

rise to SetPoint Medical's implantable bioelectronic device, which automatically

stimulates the vagus nerve for sixty seconds a day, engaging what Tracey calls the

"inflammatory reflex."

In 2025, the FDA approved the device for rheumatoid arthritis — the first vagus nerve

stimulator cleared for an inflammatory autoimmune condition. The pivotal trial was a

rigorous, double-blind, sham-controlled study in which active stimulation outperformed sham by a substantial margin, with results continuing to improve over a year of

follow-up (see note 2). The device is not yet approved for any other indication.

The healthspan relevance reaches beyond the approved RA indication. Inflammaging

— the chronic, low-grade inflammation that accumulates with biological aging — is

mechanistically implicated in virtually every major age-related condition: Alzheimer's

disease, cardiovascular disease, metabolic syndrome, Parkinson's disease, cancer. A

device that durably resets the inflammatory setpoint, without immunosuppression, is

arguably the closest existing hardware to a multi-domain healthspan intervention.

Cleveland Clinic's head of clinical immunology noted at the time of approval that the

implications extend "far greater than this single indication." SetPoint has ongoing trials

in inflammatory bowel disease, multiple sclerosis, and metabolic disease.

For clinicians: The implant requires outpatient surgery, which limits its immediate uptake

in longevity wellness settings. Non-invasive transcutaneous and auricular VNS devices

(including gammaCore and Nurosym) are available with early-phase evidence, though

they lack the depth of the implantable trial data. Worth watching as the indication list

expands.

IMPLANTABLE VAGUS NERVE STIMULATION

2. BLOOD FLOW RESTRICTION TRAINING

EQUAL GAINS, FRACTION OF THE LOAD

Sarcopenia — the progressive loss of muscle mass and strength with aging — is not a

cosmetic problem. It is a driver of frailty, falls, metabolic dysfunction, and premature

death. The standard remedy is resistance training, which presents a clinical paradox:

the older adults most at risk are often those least able to tolerate the mechanical

demands of high-load exercise — the arthritic knee, the fragile cardiovascular system,

the deconditioned body that hasn't lifted anything heavy in years.

Blood flow restriction training resolves this tension. It uses pneumatic cuffs applied to

the proximal limb to partially restrict venous outflow while preserving arterial inflow,

creating the metabolic stress and hormonal response of high-intensity exercise at a

fraction of the mechanical load — typically 20–30% of one-repetition maximum rather

than the 60–70% required for conventional resistance training.

In head-to-head randomized trials in sarcopenic adults aged 65 and older, blood flow

restriction training at low loads has produced muscle strength gains equivalent to

conventional high-load resistance training, a finding confirmed across multiple trials

and a 2024 meta-analysis of fourteen RCTs. FDA-cleared devices (Delfi, SmartCuffs,

Kaatsu) are already in use in a number of longevity practices. Patients can also use

them between clinic sessions.

Caveat: The gains are most consistent for muscle strength rather than mass, and no

blood flow restriction-specific trial has yet linked the intervention directly to reduced fall

rates or mortality. The clinical logic is compelling, but those longer-chain outcomes

remain to be demonstrated

3. WHOLE-BODY VIBRATION

PASSIVE RESISTANCE FOR THOSE WHO CAN’T TRAIN

Whole-body vibration platforms — the vibrating plates found increasingly in physical

therapy suites and upscale gyms — deliver mechanical oscillations at 20–50 Hz through

a standing or seated patient, stimulating neuromuscular activation, proprioceptive

adaptation, and hormonal response without requiring active exercise effort. For the most

deconditioned or mobility-limited older adults, this can be the difference between

receiving some form of muscle stimulus and receiving none.

Across a systematic review of eighteen randomized controlled trials, whole-body

vibration produced significant improvements in lower limb muscle strength and

explosive power in older adults. A 2025 trial directly comparing the approach with

conventional resistance training in sarcopenic adults found the two broadly equivalent

on physical performance outcomes — a finding that positions whole-body vibration as a

genuine clinical alternative, not a softer substitute. A 2025 scoping review of eight years

of literature found additional cardiovascular benefits, including improved endothelial cell

function and increased skin blood flow. Small randomized trials also show bone density

improvements, adding osteoporosis to the list of aging conditions this device may

benefit.

Best position: A complement to resistance exercise rather than a replacement —

particularly useful for the most frail patients in longevity clinic settings.

A STRONG AND GROWING MIDDLE

MULTIPLE TRIALS, EVOLVING PROTOCOLS

4. PHOTOBIOMODULATION

A VERY BROAD EVIDENCE BASE

Photobiomodulation — applying red and near-infrared light at specific wavelengths to

biological tissue — has an evidence base that spans more organ systems by far than

other devices discussed in this article. The mechanism is specific: photons in roughly

the 630–1070 nm range are absorbed by cytochrome c oxidase in the mitochondrial

electron transport chain, stimulating ATP production, reducing oxidative stress, and

modulating inflammation. That mechanism connects directly to several hallmarks of

aging, which may explain in part why the literature has expanded in so many directions

over time.

For the brain, which is probably the highest-stakes target for longevity medicine, a 2024

systematic review in GeroScience covering 37 studies found promising results for the

treatment and prevention of age-related cognitive impairment. Vielight, whose devices

combine transcranial and intranasal delivery, has clinical data showing meaningful

cognitive improvement in early dementia patients — well above placebo results in

controlled trials (see note 3). In a Parkinson's disease trial, walking speed improved substantially after twelve weeks of combined photobiomodulation and exercise. An umbrella review published in 2025 confirmed effects across pain, neurological conditions, wound

healing, and tissue repair.

The breadth is the appeal and the challenge. Wavelength, power density, pulse

frequency, session duration, and anatomical target all vary considerably across trials,

which makes it genuinely difficult to distill a single protocol recommendation. The most

rigorous evidence to date is for transcranial and intranasal delivery for cognitive aging.

Targeted clinic-grade devices are meaningfully different from the consumer panels sold

online; dose matters.

Caveat: No large definitive trial with hard clinical endpoints has yet been completed.

The evidence is promising but still primarily drawn from smaller trials and surrogate

outcomes.

5. A VERY BROAD EVIDENCE BASE

THE MOST DIRECT AGING BIOLOGY DATA

Hyperbaric oxygen therapy places a patient inside a pressurized chamber and has them

breathe 100% pure oxygen at 1.5–3 atmospheres absolute — far above the

atmospheric pressure at sea level. Under these conditions, oxygen dissolves directly

into plasma rather than relying solely on hemoglobin, driving concentrations into hypoxic

tissue, suppressing inflammation, stimulating growth factors, mobilizing stem cells, and

activating mitochondrial biogenesis. Those mechanisms connect directly to several

hallmarks of aging. If you wanted to design a device study that spoke directly to the

biology of aging — not a disease symptom, not a functional score, but the underlying

cellular machinery — you would be hard-pressed to improve on what Shai Efrati's group

at Tel Aviv's Sagol Center published in 2020. Sixty sessions produced telomere

lengthening of over 20% in multiple immune cell populations, alongside a reduction in

senescent immune cells of up to 37% (see note 4). These are among the only published human data showing telomere elongation from any intervention.

For cognition, a study in healthy active older adults — not people with dementia, just

people aging normally — found significant improvements in attention, processing speed,

and executive function after a hyperbaric oxygen protocol. A 2024 meta-analysis

across eleven randomized controlled trials in Alzheimer's patients found consistent

improvements in cognitive scores and functional measures, alongside reductions in

inflammatory markers (see note 5).

The practical reality: Hyperbaric oxygen requires 40 or more sessions of 60 to 90

minutes each, in specialized pressurized chambers. The equipment is expensive; the

time commitment is substantial. Aviv Clinics, which operates at several sites

internationally, has been the most visible commercial translation of Efrati's research.

The senescence and telomere data are striking — but replication in larger trials is

desirable, and protocol standardization (pressure, duration, number of sessions)

remains an open question. It is worth noting that the evidentiary bar for devices is

structurally lower than for drugs: the FDA's device pathways do not require the phase III randomized trial evidence that drug approval demands, which means that even the

most robust device datasets — HBOT's included — may lack the optimized

dose-response characterization and long-term durability data that pharmaceutical

regulators routinely require. This is a feature of the device regulatory landscape

generally, not a specific weakness of HBOT.

6. FINNISH SAUNA AND PASSIVE HEAT

THE EPIDEMIOLOGY YOU CAN’T IGNORE

Few non-pharmacological interventions have produced a population-level signal as

large and consistent as regular Finnish sauna use — yet it rarely features in longevity

device discussions, perhaps because it seems too traditional, too pleasurable, or too

removed from the clinic to be taken seriously as medicine. That impression is worth

revisiting.

The foundational data comes from the Kuopio Ischemic Heart Disease Risk Factor

Study — a prospective cohort of over 2,300 middle-aged Finnish men followed for up to

27 years. Published in JAMA Internal Medicine in 2015, the headline finding was stark:

men who used the sauna four to seven times per week had a 40% reduction in

all-cause mortality and a 50% reduction in fatal cardiovascular events compared to

those who used it once weekly, after adjusting for physical activity, BMI, socioeconomic

status, and conventional cardiovascular risk factors (see note 6). The relationship was

dose-dependent — more frequent, longer sessions, stronger protection — with no

apparent floor effect.

The same cohort subsequently found that the most frequent sauna users had a 66%

lower risk of developing dementia and a 65% lower risk of Alzheimer's disease (see note 7). A 2018 extension of the analysis to both men and women confirmed the cardiovascular

mortality findings and showed that sauna frequency added independent predictive value

to standard cardiovascular risk models. More recent analyses from the same cohort

have associated regular sauna use with lower rates of psychosis, pneumonia, and

sudden cardiac death.

The biological mechanisms are plausible and multi-factorial (see note 8). A Finnish sauna session raises heart rate to 120–150 beats per minute, increases cardiac output, and

temporarily dilates blood vessels — mimicking the cardiovascular response of moderate aerobic exercise. Repeated heat exposure induces heat shock proteins, which protect

cells against oxidative and proteotoxic stress and are associated with longevity across

multiple model organisms. Brain-derived neurotrophic factor, which supports

neurogenesis and is linked to dementia protection, rises in response to the

cardiovascular challenge. Inflammatory markers improve. Arterial compliance increases

over time.

A 2024 comprehensive review of passive heat therapies concluded that Finnish saunas

have the most consistent and robust evidence among all passive heat modalities, with

benefits spanning cardiovascular disease, dementia, respiratory conditions,

musculoskeletal health, mental wellbeing, and sleep. The same review notes that

combining sauna with regular physical activity appears synergistic — each amplifying

the benefits of the other.

Evidence quality: The KIHD data is observational — a powerful and well-controlled

prospective cohort, but not a randomized trial. Most of it comes from Finnish men with

lifelong sauna habits, and at least one well-designed short-term RCT did not find the

expected vascular mechanism in a coronary artery disease population after eight weeks

of use. Definitive controlled trials measuring hard longevity endpoints are difficult to

design and remain absent. That said, the magnitude, duration, consistency, and

dose-response character of the epidemiological signal are among the strongest in the

healthspan literature for any passive intervention.

Practical access — and this matters: The trial data points to three to seven sessions per

week, each lasting fifteen to twenty minutes, at temperatures of 80–100°C. That

frequency is not achievable on occasional visits to a spa. It requires routine access —

which for most people means one of three things: a gym or athletic club with a

Finnish-style dry sauna (not a steam room), a membership at a bathhouse or Nordic

spa that offers traditional sauna, or a home installation.

Home sauna installations have dropped substantially in price in recent years. Barrel

saunas and modular infrared units from companies like Finnleo, Almost Heaven, and

Sun Home start at a few thousand dollars for a basic outdoor model; higher-end

traditional electric sauna rooms suitable for regular use run $5,000–$15,000 depending

on size and configuration. For patients committed to frequency, a one-time home

installation may be more practical — and far more likely to produce the consistent use

the data supports — than relying on clinic or spa access. Infrared saunas operate at

lower temperatures (50–60°C) than traditional Finnish saunas; their evidence base is related but not identical, and the KIHD data was collected specifically in traditional dry

sauna conditions.

7. TRANSCRANIAL MAGNETIC STIMULATION

A NEW ROLE FOR AN ESTABLISHED DEVICE

Repetitive transcranial magnetic stimulation uses rapidly alternating magnetic fields to

induce electrical currents in cortical neurons — non-invasive neuromodulation at

targeted brain regions, no implant required. It has been FDA-cleared for depression,

obsessive-compulsive disorder, and smoking cessation for years. What is less

appreciated is that its evidence base for cognitive aging has grown substantially.

A 2024 meta-analysis pooling data from 25 randomized controlled trials found that

transcranial magnetic stimulation significantly improved memory and thinking scores

compared to sham stimulation in patients with Alzheimer's disease, with moderate to

large effect sizes across standard cognitive batteries. Targeting the dorsolateral

prefrontal cortex consistently produced the best results. A 2025 paper in Nature

Neuropsychopharmacology made a mechanistically important argument: impaired

cortical synaptic plasticity is what connects late-life depression to cognitive decline, and

plasticity-inducing neuromodulation may reduce dementia risk through a direct

neuroprotective mechanism — not merely by treating depressive symptoms.

Why this matters for longevity clinics: Late-life depression is a meaningful risk factor for

dementia. A non-pharmacological, FDA-cleared intervention for depression that may

also protect neural circuitry against age-related decline sits in an interesting position: it

is already reimbursable for depression, and its potential scope is considerably broader.

The approved indication is depression; the longevity case rests on the

depression-to-dementia pathway and the emerging direct evidence in Alzheimer's — a

gap the ongoing trial program is actively working to close. The effect in Alzheimer's is

improvement in the rate of cognitive decline, not reversal — and optimal stimulation

protocols for aging populations are not yet standardized.

8. TRANSCRANIAL PULSE STIMULATION

ACOUSTIC NEUROMODULATION FOR COGNITIVE AGING

Transcranial pulse stimulation uses brief, low-intensity acoustic pulses delivered

non-invasively through the skull to modulate neural activity — without destroying tissue.

Unlike high-intensity focused ultrasound platforms used in neurosurgical applications,

TPS operates at low energy levels: its mechanism involves mechanical stimulation of

neurons that appears to induce neuroplastic changes in network connectivity and

synaptic function, rather than thermal ablation. This low-intensity, non-ablative profile

makes TPS compatible with outpatient clinical settings and relevant to longevity

medicine in a way that ablative neurosurgical approaches are not.

A randomized, double-blind, sham-controlled crossover trial published in JAMA Network

Open in February 2025 enrolled sixty Alzheimer's patients at the Medical University of

Vienna and found that two weeks of TPS produced significant cognitive improvement in

a younger subsample of patients, alongside measurable changes in memory-associated

brain network connectivity. A one-year feasibility study showed sustained

neuropsychiatric benefit.

The longevity relevance is straightforward: cognitive aging and early Alzheimer's

disease are among the highest-stakes targets in healthspan medicine. A non-invasive

acoustic neuromodulation approach that produces measurable improvements in

network connectivity — without the equipment and clinical infrastructure requirements of

MRI-guided platforms — has a plausible path into longevity clinic settings, particularly in

European and APAC markets where TPS devices are already in clinical use.

Caveat: The evidence base is newer and smaller than for TMS; the cognitive effect in

the Vienna trial was most pronounced in younger patients within the Alzheimer's

sample; durability of benefit beyond one year is unclear. TPS devices are available in

several European and APAC markets but are not yet cleared in the United States.

Regulatory status varies by country. The field is moving quickly.

EARLIER IN THE EVIDENCE CURVE

BUT WORTH KNOWING

9. INTERMITTENT HYPOXIA-HYPEROXIA TRAINING

THE NOBEL-WINNING PATHWAY, IN A BOX

In 2019, the Nobel Prize in Physiology or Medicine went to the researchers who

deciphered HIF-1α — the master transcription factor that cells use to sense and

respond to oxygen levels. Brief hypoxia activates HIF-1α, triggering a cascade of

cellular adaptations that overlap substantially with what vigorous exercise produces:

improved mitochondrial function, cardiovascular adaptation, metabolic efficiency, and

anti-inflammatory signaling.

Intermittent hypoxia-hyperoxia training cycles patients through breathing hypoxic air

(10–15% oxygen) alternating with hyperoxic air (30–40% oxygen) in repeated intervals

— essentially delivering a controlled oxygen stress in a supervised clinical setting. The

appeal for longevity medicine is that it may provide exercise-mimetic cellular benefits to

patients who are too frail or deconditioned to achieve them through exercise itself.

A meta-analysis of fourteen randomized controlled trials found significant reductions in

resting heart rate and blood pressure, with no serious adverse events. A 24-week

study in healthy adults aged 65–75 found reductions in fat mass, C-reactive protein, and

improvements in bone remodeling markers compared to controls. The ReOxy device (Ai

Mediq) is CE-marked in Europe and in clinical use at cardiac and longevity centers in

Germany, Austria, and Switzerland.

Caveat: The trials are generally small and primarily European. No large definitive trial

with hard outcomes exists. Commercial claims from device vendors outpace the

published evidence. A promising mechanism, an emerging evidence base, and a need

for more independent research.

10. COLD WATER IMMERSION

BIOLOGY THAT RUNS AHEAD OF THE DATA

Cold water immersion has traveled rapidly from the athletic recovery room to the

mainstream — accelerated by the Wim Hof phenomenon, proliferating cold plunge

facilities, and a genuine if still incomplete scientific rationale. The biology is plausible

and mechanistically interesting: immersion in water at 2–15°C triggers a surge of

noradrenaline, activates brown adipose tissue, induces cold shock proteins (the cold

counterpart to heat shock proteins), and may drive improvements in insulin sensitivity,

mitochondrial biogenesis, and immune function. These are pathways that connect to

aging hallmarks.

The most rigorous published evidence to date is a January 2025 systematic review and

meta-analysis in PLOS ONE examining eleven randomized controlled trials involving

3,177 participants. The reviewers found time-dependent improvements in stress

markers, sleep quality (in men), and quality of life scores. A 2025 PMC review is

cautiously optimistic about cold water therapy for healthy aging, but is frank that the

evidence is "less consistent and primarily based on non-RCT studies with limited

sample sizes" compared to passive heat therapies.

That contrast with sauna is worth being explicit about. The Finnish sauna data from the

Kuopio cohort — 40% reduction in all-cause mortality, followed over 27 years across

more than 2,300 participants — has no parallel in the cold immersion literature. The

cold data is measured in weeks and wellness outcomes; the heat data is measured in

years and death rates. That gap could narrow with larger, longer trials. It has not closed

yet.

Cold and heat are increasingly paired in "contrast therapy" sequences at longevity

clinics and wellness resorts — alternating sauna and cold plunge sessions to activate

complementary adaptive pathways (heat shock proteins and cold shock proteins;

cardiovascular dilation and vasoconstriction). The physiological rationale for synergy is

reasonable; the evidence for a benefit specifically from the combination, beyond what

either modality produces alone, is not yet established (see note 9).

Safety note: Cold water immersion carries real cardiovascular risk for anyone with

coronary artery disease, hypertension, or circulatory conditions. Physician clearance is

appropriate before initiating a protocol. The "cold shock" gasp reflex in open water immersion is a documented drowning hazard — relevant particularly for unsupervised

natural water exposure.

11. VESTIBULAR BALANCE TRAINING

THE FALL PREVENTION TECHNOLOGY

Falls are the leading cause of injury-related death in adults over 65. A hip fracture in

someone over 80 carries a one-year mortality rate of 20–30%. Strength training helps

— but there is a mechanism that pure strength cannot address: the vestibular system,

the inner ear's gravity-sensing apparatus, degrades measurably with age, and its

decline is a primary driver of the balance impairment that leads to falls.

Technology-enabled vestibular rehabilitation targets this directly.

A 2024 study published in Communications Biology enrolled 40 healthy adults aged 70

to 88 in a two-week perceptual learning intervention on a motion platform. Vestibular

thresholds improved by approximately 30% on average, and postural sway and gait

parameters improved significantly, yielding a more dynamic and confident gait pattern.

Neursantys represents a highly integrated commercial model of this approach,

combining diagnostics and therapeutics into a single wearable device placed behind the

ear. Diagnostically, the device measures physiological micro-vibrations (phybrata) to

establish a fall-risk biomarker that recently demonstrated a highly accurate 0.88 AUC

predictive value — substantially outperforming standard clinical balance tests.²⁵

Therapeutically, a 2025 pilot randomized controlled trial in 40 older adults found that

using the device to deliver low-amplitude wideband electrical vestibular stimulation

(EVS) three times per week for six weeks induced profound neuroplastic restorations of

balance. The magnitude of improvement was sufficient to clinically recategorize high

fall-risk patients to lower-risk tiers, with measurable improvements beginning by the

third session and persisting for at least six months post-treatment.

Caveat: Trial sizes are small and protocols are heterogeneous; the specific link from

vestibular improvement to reduced fall rates and mortality in large trials remains to be

established, but the early data is rather stunning. The underlying rationale is strong, the

safety profile is excellent, and the technology is accessible in clinical settings. Given

how devastating falls are in older adults, this category deserves more attention than it

currently receives.

12. WHOLE-BODY RED LIGHT AND NEAR-INFRARED PANELS

Full-body red and near-infrared light panels — distinct from the clinic-grade targeted

photobiomodulation discussed earlier — are proliferating in longevity wellness settings.

The underlying mechanism is the same: mitochondrial stimulation and anti-inflammatory

signaling via cytochrome c oxidase. The difference is delivery: whole-body rather than

targeted, at consumer-grade power levels rather than the higher irradiances used in

clinical settings (typically 10–100 mW/cm² for clinical-grade devices versus the lower

output of most consumer panels; safety limits for whole-body exposure are not yet

formally standardized for either category, though thermal and photochemical injury

thresholds guide clinical practice). Randomized trial evidence supports effects on musculoskeletal pain and athletic recovery,²⁶ but the dose-response relationships for

systemic aging-relevant outcomes are not well characterized. Low-risk and inexpensive

relative to most devices on this list; best positioned as a complement to higher-evidence

approaches rather than a standalone.

13. PULSED ELECTROMAGNETIC FIELD THERAPY

Pulsed electromagnetic field therapy has an FDA-cleared application for non-union bone

fractures — a meaningful regulatory anchor — and a handful of small randomized trials showing effects on bone density, inflammatory markers, and early-stage osteoarthritis.²⁷ The mechanistic pathway involves adenosine receptor activation and calcium ion channel modulation. The principal challenge is that the wellness-oriented end of this market (Bemer, iMRS, and similar mat-based consumer devices) has substantially outpaced the peer-reviewed evidence, and device quality standards are inconsistent. The most defensible clinical applications remain in bone and joint health, where the evidence is most developed.

MEANING FOR STAKEHOLDERS

FOR PRACTITIONERS AND LONGEVITY CLINICS

Blood flow restriction training, whole-body vibration, targeted photobiomodulation, and

vestibular balance training together constitute a well-evidenced, accessible, low-risk

device toolkit for addressing frailty, sarcopenia, and fall risk — aging conditions most

directly addressable with current hardware. Hyperbaric oxygen therapy and repetitive

transcranial magnetic stimulation add evidence-based options for cognitive aging and

neuropsychiatric conditions. Sauna infrastructure belongs in any serious longevity

wellness program given the magnitude and consistency of its epidemiological record.

Cold immersion protocols can be offered alongside sauna as part of thermal hormesis

programming, with appropriate medical screening and honest communication about

where the evidence currently stands.

One practical observation worth making: longevity medicine clinicians may find

device-based interventions easier to offer than off-label drugs or early-stage compounds — typically for reasons of safety profile, patient acceptance, and the straightforward reimbursement pathways that already exist for several of these technologies in rehabilitation and neurology settings.

FOR PRODUCT DEVELOPERS AND ENTREPRENEURS

The devices described here do not exist in isolation from the rest of the longevity toolkit.

Hyperbaric oxygen, blood flow restriction, and intermittent hypoxia-hyperoxia all activate

cellular pathways — HIF-1α, mTOR, AMPK, growth hormone — that are also primary

targets of longevity drugs. Photobiomodulation and vagus nerve stimulation modulate

neuroinflammatory and mitochondrial pathways that senolytics and NAD+ precursors

target pharmacologically.

This suggests an intriguing near-term development opportunity: intentional stacking of

device plus drug, and/or device plus lifestyle intervention, where each modality

addresses a complementary node in aging biology. The $101 million XPRIZE

Healthspan competition — whose 100 semifinalists span biologics, drugs, lifestyle

interventions, medical devices, and nutraceuticals — notes that many teams are pursuing combination strategies, but device-centric or device-inclusive stacks are

underrepresented among the most prominent entries.²⁸ ARPA-H's PROSPR program

similarly funds multi-modal approaches to healthspan. There is room for developers to

propose projects that give devices an explicit role in the stack, not just as adjuncts but

as direct interventions on primary mechanisms.

FOR INVESTORS

The medtech investment landscape looks structurally different from biopharma — and in

ways that may be underappreciated in the longevity context. FDA clearance via the

510(k) pathway has a median review time of around five months; drug approval requires

well over a decade of clinical development. Both PMA-level device deals and 510(k)

exits showed strong M&A valuations in 2024, with PMA deal medians reaching $810

million total value.²⁹ Large medtech acquirers — Medtronic Ventures, Johnson &

Johnson Innovation, Boston Scientific — have increased their allocations to early-stage

healthtech, and the pattern in recent years is that pivotal trial completion is often the

acquisition trigger, not commercial launch.

Several categories in this piece look interesting through that lens. SetPoint Medical is

widely discussed in medtech investment circles as a near-term acquisition candidate:

the company has secured strategic backing from both Boston Scientific and Abbott (two

of the dominant players in neuromodulation), raised approximately $580 million in total

— including a $140 million Series D in August 2025 that included an undisclosed

strategic investor — and achieved FDA approval at the end of 2025. PitchBook's

late-2025 healthcare outlook assigned SetPoint an 87% "Exit Predictor" probability. In

medtech, the typical acquisition trigger is commercial de-risking rather than pivotal trial

completion; the prevailing thesis is that once SetPoint establishes reimbursement codes

and early sales traction in 2026, one of its strategic backers will move. SetPoint

Medical's 2025 FDA approval was the first in a franchise play — vagus nerve

stimulation for rheumatoid arthritis is one indication, with inflammatory bowel disease,

multiple sclerosis, and metabolic disease in the pipeline. Transcranial magnetic

stimulation for dementia, if it achieves a specific Alzheimer's indication, would enter an

enormous reimbursable market with an installed base of existing clinic infrastructure.

The broader point is that private longevity investment more than doubled in 2024,

reaching $8.49 billion,³⁰ almost entirely in drugs, diagnostics, and biotech. The device subcategory remains proportionally small — which may mean the field is underweighted

relative to the evidence.

FOR POLICYMAKERS AND REGULATORS

None of the devices in this piece — not even the FDA-approved vagus nerve stimulator

— holds regulatory authorization for a healthspan claim. Each is cleared or approved for

a specific disease: hyperbaric oxygen for wound healing, transcranial magnetic

stimulation for depression, vagus nerve stimulation for rheumatoid arthritis. The

regulatory architecture for multi-domain aging benefit claims does not yet exist for

devices, any more than it does for drugs. The TAME trial — a proposed landmark study

testing whether metformin can delay multiple chronic diseases of aging simultaneously,

using a composite basket of conditions as the primary endpoint — represents one

model for how that might change, and could be extended to device studies.

Proposed legislation from the Kitalys Institute — the THRIVE Act (Therapeutic

Healthspan Research, Innovation, and Validation Enhancement Act) — would establish

an optional tiered regulatory pathway for drugs, devices, and supplements intended to

increase healthspan.³¹ Its three-tier "earn it or lose it" structure would allow earlier

market access while requiring sponsors to generate increasing levels of clinical

evidence over time. Importantly, THRIVE explicitly includes medical devices in its scope

and mandates a dedicated FDA Center for Healthspan Products to evaluate drugs,

devices and supplements that claim to extend healthspan. For the categories described

in this article, THRIVE could provide the regulatory on-ramp that currently does not exist

— not replacing disease-specific clearances, but enabling multi-indication healthspan

claims where the evidence supports them. ARPA-H's PROSPR program, funding

interventions targeting the earliest biological changes of aging, is a further sign that the

policy conversation is beginning to move.

The policy imperative extends beyond product approval to reimbursement. The

longevity dividend — the reduction in downstream healthcare costs that flows from

keeping populations healthier for longer — is massive — estimated by Goldman,

Olshansky et al. at $7.1 trillion in economic value over fifty years from even modest

aging delays, and by Scott, Ellison, and Sinclair at $38 trillion per additional year of

healthy life gained³² — but requires the political will and business model adjustments to

fund preventive interventions whose payoff accrues over years or decades. Private payers face a structural short-termism problem: the entity that pays for a sauna

installation or a hyperbaric oxygen protocol today is unlikely to be the entity that saves

on avoided dementia care in fifteen years. Public payers in theory should want to bank

the long-term savings, but are just as subject to the political pressures of short-termism.

THRIVE's parallel FDA-CMS collaborative review process is a start to address this

misalignment, by creating reimbursement pathways alongside regulatory ones, so that

evidence-supported interventions can reach patients rather than being limited to

self-pay longevity clinics. For policymakers, the question is not only what the FDA

should approve, but what Medicare, Medicaid, and commercial insurers should cover —

and whether the evidence thresholds for reimbursement can be calibrated to the

magnitude of the potential population-level benefit.

FOR GEROSCIENTISTS

Devices and drugs need not be separate research agendas. Hyperbaric oxygen and

blood flow restriction training both activate pathways — HIF-1α, mTOR, AMPK, growth

hormone — that are primary targets of gerotherapeutic drugs. Photobiomodulation and

vagus nerve stimulation modulate neuroinflammatory and mitochondrial pathways that

senolytics and NAD+ precursors target pharmacologically. An intriguing research design

may be device-plus-drug combination trials, where each modality addresses a

complementary node in the aging biology network.

FOR THE CURIOUS

A number of these interventions are available now, some more accessible than others.

Finnish-style sauna has the strongest population-level evidence of any passive

intervention in this piece, and the most practical path to the dose the data supports is a

gym membership with a traditional dry sauna or a home installation — both increasingly

affordable. Blood flow restriction and whole-body vibration can both be accessed

through physical therapy or structured fitness programs. Transcranial photobiomodulation devices are available commercially, with the caveat that dose standardization is still evolving and consumer products vary enormously. Cold plunge facilities are easy to find in most cities, and the evidence, while still early, is sufficient to make the practice worth considering for otherwise healthy individuals. Hyperbaric oxygen and transcranial magnetic stimulation are available at a growing number of specialized clinics. Transcranial pulse stimulation is available in European and APAC markets and is likely to expand its footprint as the clinical evidence develops. Effective interventions for aging may be thermal, mechanical, electrical, and acoustic — not only molecular. Useful to remember, for stakeholders in healthy longevity.

The potential of molecular targeting of aging, to pharmacologically delay or reverse

aging; diagnostic devices that are biomarkers of aging; and lifestyle modifications are

key foci in the growing attention on healthy longevity. But interventional medical devices

such as those discussed above, available now or in the near term, have been

developing a body of clinical evidence for direct impact, not just for supportive roles.

Achieving healthy longevity for all will take different approaches and modalities for different people, at different stages of life, with different risk tolerances and access points. Interventional medical devices deserve a seat in the longevity conversation.

Thomas Seoh is CEO of Kinexum, a regulatory, clinical, product and corporate

development strategic advisory firm, and EVP of its not-for-profit

Kitalys Institute. Since 2017, Kinexum and Kitalys have organized the

Targeting Healthy Longevity (previously called Targeting Metabesity) conference,

convening leaders of NIH, FDA, Congress, the UK Parliament, geroscience and chronic

disease research, industry and capital markets in furtherance of the Kitalys mission to

catalyze the translation of science into public health to prevent chronic diseases and

extend healthy longevity for all. Over 200 conference sessions are posted on Kitalys's

YouTube channel. Kitalys has advised XPRIZE Healthspan and ARPA-H PROSPR on strategic regulatory matters, and Kinexum represents a number of LongBio (longevity biotechnology) companies, including semi-finalists in XPRIZE Healthspan.

Kitalys is partnering this year with the Asia-Pacific Longevity Medicine Society to

present the Asia-Pacific Healthy Longevity International Summit in Hong Kong October

1-4, 2026 (register here), where one of the planned sessions will be on

Interventional Medical Devices for Healthy Longevity.

NOTES

1. Underrepresentation of interventional devices is evident across multiple longevity forums. The 7wire Ventures 2025 longevity market analysis segments the field into Therapeutics & Drug Discovery ($2.1B), Cellular Rejuvenation, Agetech & Cognitive Health, and Consumer Diagnostics & Care ($3.5B) — without naming device interventions as a category. The PMC review "Climbing the Longevity Pyramid" (2024) devotes most of its space to pharmaceuticals, biomarkers, and lifestyle factors while treating hardware interventions as peripheral. That pattern is consistent across most major longevity conference programs and investor summaries.

2. Active VNS achieved ACR20 response of 35.2% vs 24.2% sham at 3 months; improving to 52.8% at 12 months in open-label extension; average 60% reduction in tender and swollen joint counts at 12 months. Reported in Nature Medicine 2025.

3. MoCA score improvement of 3.20 points vs 1.97 placebo at 60 days; improved cerebral perfusion and fMRI network connectivity in dementia trials; ~50% walking speed improvement in Parkinson's disease at 12 weeks. Systematic Reviews 2025.

4. Telomere length increased >20% across T helper, T cytotoxic, NK, and B cells; senescent T helper cells reduced by up to 37%. Aging 2020.

5. Significant improvements in MMSE, ADAS-Cog, and ADL scores; reduced oxidative stress markers and inflammatory cytokines; no serious adverse events. Front Aging Neurosci 2024.

6. 4–7 sessions/week: HR 0.60 for fatal CVD and all-cause mortality vs once weekly, adjusted for physical activity, BMI, SES, and CVD risk factors. Dose-response with no threshold. JAMA Intern Med 2015.

7. Finnish sauna 4–7x/week associated with 66% lower risk of dementia and 65% lower risk of Alzheimer's disease vs once-weekly use in KIHD cohort. Exp Gerontol 2021.

8. Mechanisms include cardiovascular challenge (HR 120–150 bpm), heat shock protein induction, BDNF upregulation, anti-inflammatory effects, and arterial compliance improvement. Mayo Clin Proc 2018.

9. The physiological rationale for contrast therapy — alternating heat and cold activating complementary adaptive pathways through vasodilation/vasoconstriction cycling, heat shock protein induction, and noradrenaline release — is established, though evidence of benefit specifically from the combined protocol beyond what either modality produces independently remains limited. The foundational mechanistic review remains, "What is the biochemical and physiological rationale for using cold water immersion in sports recovery?" (Bleakley CM, Davison GW. Br J Sports Med 2010;44(3):179–187). More recent literature has not produced a definitive RCT of the contrast combination in older adults or with longevity endpoints; Kunutsor et al. (2025, PMC11872954) and the 2024 passive heat therapy review (PMC10989710) both note this gap.

²⁵ King, J. A., et al. (2025). Phybrata Digital Biomarkers of Age-Related Balance Impairments and Fall Risk. Sensors, 25(12), 3624. DOI: 10.3390/s25123624. The Neursantys device measures physiological micro-vibrations (phybrata) via a wearable sensor placed behind the ear; fall-risk prediction AUC of 0.88, substantially outperforming standard clinical balance tests. Same device platform used in the 2025 noisy electrical vestibular stimulation (nEVS) pilot RCT (n=40, mean age 77.7): 6 weeks of low-amplitude wideband electrical stimulation 3x/week; improvements sufficient to recategorize high-fall-risk patients to lower-risk tiers, with measurable gains beginning by the third session and persisting at least 6 months post-treatment. J Neuroeng Rehabil 2025.

²⁶ Leal-Junior EC, Vanin AA, Miranda EF, et al. "Effect of phototherapy (low-level laser therapy and light-emitting diode therapy) on exercise performance and markers of exercise recovery: a systematic review with meta-analysis." 13 of 16 RCTs showed significant improvement in muscle performance outcomes; phototherapy improved time to exhaustion and number of repetitions; evidence supports musculoskeletal pain reduction and athletic recovery. Lasers Med Sci 2015;30(2):925–939 (PMID 24249354).

²⁷ Hannemann PF, Mommers EH, Schots JP, Brink PR, Poeze M. "The effects of low-intensity pulsed ultrasound and pulsed electromagnetic fields bone growth stimulation in acute fractures: a systematic review and meta-analysis of randomized controlled trials." Meta-analysis of 13 RCTs: subgroup analyses showed significant reduction in time to radiological union for non-operatively managed fractures and upper extremity fractures. Arch Orthop Trauma Surg 2014;134(8):1093–1106 (PMID 24895156).

²⁸ XPRIZE Healthspan ($101M, 7-year competition, launched 2023) selected 100 semifinalists from 600+ teams across 58 countries in May 2025. The most prevalent solution categories include biologic therapies, drugs and small molecules, lifestyle interventions, medical devices, and nutraceuticals. Many teams propose combination strategies — diet paired with drugs or cell therapies — though device-centric or device-inclusive combination stacks appear underrepresented among the most prominent entries. XPRIZE Healthspan Milestone 2 finalists to be announced July 2026; grand prize awarded 2030. XPRIZE Healthspan, xprize.org. 29 HSBC 2024 Annual Venture Healthcare Report (analysis by Nocturnal, February 2025). PMA device M&A: median up-front payments of $550M and total deal values of $810M in 2024. Median exit timelines: 13.8 years (PMA), 11.1 years (510(k)). Early-stage medtech investment: $971M across 106 deals in 2024, up 34% from 2023. 30 Private longevity investment reached $8.49 billion across 325 deals in 2024, more than doubling 2023 levels ($3.82B). Longevity.Investment data, reported in Newsweek, March 2026.

³¹ The THRIVE Act (Therapeutic Healthspan Research, Innovation, and Validation Enhancement Act) is draft legislation prepared by the Kitalys Institute (Spring 2026) creating an optional tiered regulatory pathway for drugs, devices, and supplements intended to increase healthspan — defined as preventing or reversing two or more major age-related chronic diseases including cardiovascular disease, type 2 diabetes, Alzheimer's disease, Parkinson's disease, frailty, and others, see: https://bit.ly/3PNvqMI. The three-tier "earn it or lose it" system allows earlier market access while requiring ongoing evidence generation. Key incentives include up to 15 years of claim exclusivity per tier, priority review vouchers at Tier 3, and up to five $100M innovation prizes. THRIVE mandates a Center for Healthspan Products within the FDA and parallel FDA-CMS review to address reimbursement. Kitalys Institute, www.kitalys.org.

³² Goldman DP et al. Health Affairs 32(10):1698–1705 (2013); Scott AJ, Ellison M, Sinclair DA. Nature Aging 1:616–623 (2021).

APPENDIX: EVIDENCE REFERENCE TABLE

A consolidated reference across all thirteen device categories, organized by evidence

tier for ease of comparison.

#	Device / Modality	Evidence Tier	Evidence Basis	Clinic / Consumer Access	Primary Aging Target
BEST-EVIDENCED: HARDWARE WITH A CLINICAL TRACK RECORD
1	Vagus Nerve Stimulation (Implantable)	A — Pivotal RCT; FDA-approved 2025	Sham-controlled trial (n=242); ~60% joint improvement at 12 months	Specialist referral required	Inflammaging; multi-disease
2	Blood Flow Restriction Training	A — Multiple RCTs / meta-analysis	14-RCT meta-analysis; gains equal to high-load resistance training at fraction of mechanical load	High (in-clinic + home cuffs)	Sarcopenia, frailty
3	Whole-Body Vibration	A/B — Multiple RCTs / meta-analysis	18-RCT review; 2025 RCT: equivalent to resistance training in sarcopenic adults	High	Muscle, balance, bone
STRONG AND GROWING MIDDLE: MULTIPLE TRIALS, EVOLVING PROTOCOLS
4	Photobiomodulation (Targeted)	B — Multiple RCTs; umbrella review	2024 GeroScience review (37 studies); significant cognitive and mobility improvement in Parkinson's and dementia trials	High (in-clinic; devices commercially available)	Brain, inflammation, mitochondria
5	Hyperbaric Oxygen (HBOT)	B — Multiple RCTs; aging biology data	Telomere lengthening >20%; senescent cells reduced 10–37%; 11-RCT Alzheimer's meta-analysis (n=847)	Moderate (specialized equipment; cost)	Senescence, cognition, neuroplasticity
6	Finnish Sauna / Passive Heat	B — Large prospectivecohorts; early RCTs	KIHD cohort (n=2,315, 27 years): 40–50% CVD mortality reduction; 66% lower dementia risk (4–7x/week)	High (gym/bath membership; home installation)	Cardiovascular, dementia, all-cause mortality
7	TMS / rTMS	B — Multiple RCTs; FDA-cleared	25-RCT meta-analysis: significant cognitive improvement in Alzheimer's; moderate-large effect sizes	High (FDA-cleared for depression)	Dementia, late-life depression, cognition
8	Transcranial Pulse Stimulation (TPS)	B — Pivotal RCT (JAMA 2025)	n=60 sham-controlled trial: significant cognitive improvement; 1-year durability data	Emerging (EU/APAC available; US not yet cleared)	Cognitive aging, Alzheimer's, neuroplasticity
EARLIER IN THE EVIDENCE CURVE — BUT WORTH KNOWING
9	IHHT (Intermittent Hypoxia-Hyperoxia)	C — Multiple small RCTs	14-RCT meta-analysis: significant BP reduction; 24-week study: reduced fat mass and inflammation	Moderate (CE-marked in EU)	Cardiovascular, metabolic, HIF-1α pathway
10	Cold Water Immersion / Ice Bath	C — 11 RCTs (2025 meta-analysis)	3,177-participant PLOS ONE meta-analysis (2025): stress reduction, sleep improvement, QoL benefit; metabolic signals promising	High (widely accessible; home installations)	Stress resilience, metabolic health, inflammation
11	Vestibular Balance Training	C — Early RCTs	2024 RCT (n=40, ages 70–88): improved vestibular thresholds and gait; 2025 RCT: electrical vestibular stim improved static balance	High (if protocol-standard ized)	Falls, frailty, autonomy
12	Whole-body Red Light / PBM Panels	C — Limited RCTs	Mechanism consistent with targeted PBM; systemic dose-response not well characterized; RCT evidence for pain and recovery	High (widely deployed)	Systemic wellness, mitochondria
13	PEMF	C — Limited/mixed RCTs	FDA-cleared for bone fracture non-union; small RCTs for inflammation and bone density; consumer market has outrun the evidence	Moderate	Bone, inflammation

SELECTED FURTHER READING BY DEVICE CATEGORY

NOTES AND KEY SOURCES

Sauna / Passive Heat: Laukkanen et al. (2015) JAMA Intern Med; Laukkanen et al.

(2018) Eur J Prev Cardiol; Kunutsor & Laukkanen (2018) Mayo Clin Proc; Kunutsor et

al. (2024) PMC10989710; Patrick & Johnson (2021) Exp Gerontol 154:111509.

Cold Water Immersion: Cain et al. (2025) PLOS One PMC11778651; Kunutsor et al.

(2025) PMC11872954; Bleakley & Davison (2010) Br J Sports Med (contrast therapy

rationale).

VNS / SetPoint Medical: RESET-RA trial, Nature Medicine 2025; FDA approval,

MedCentral 2025.

Blood Flow Restriction: Brandner et al. (2024) Sci Rep; 14-RCT meta-analysis,

Frontiers Physiol 2025.

Whole-Body Vibration: 18-RCT systematic review, PubMed 2023 (PMID 37169245);

scoping review 2008–2024, PMC11927757.

Photobiomodulation: GeroScience review (37 studies) PMC11493890; umbrella review,

Systematic Reviews 2025 PMC12326686; Vielight clinical compendium; Leal-Junior et

al. (2015) Lasers Med Sci (recovery evidence).

HBOT: Hachmo et al. (2020) Aging PMID 33206062; Hadanny et al. (2021) Front Aging;

11-RCT Alzheimer's meta-analysis (2024).

TMS/rTMS: Pagali & Kumar 25-RCT meta-analysis (2024); Nature

Neuropsychopharmacology (2025).

Transcranial Pulse Stimulation (TPS): Weiss et al. (2025) JAMA Netw Open

PMC11866033.

IHHT: 14-RCT meta-analysis, ResearchGate 2021; 24-week older adult study

PMC9103404.

Vestibular Training: Buchner et al. (2024) Commun Biol; King JA et al. (2025) Sensors

25(12):3624 (phybrata fall-risk biomarker, AUC 0.88); nEVS pilot RCT, J Neuroeng

Rehabil 2025.

PEMF: Hannemann et al. (2014) Arch Orthop Trauma Surg PMID 24895156 (13-RCT

meta-analysis).

Medtech Investment: HSBC 2024 Annual Venture Healthcare Report (via Nocturnal);

PitchBook Q2 2025 MedTech VC Trends; Longevity.Investment / Newsweek 2026.

THRIVE Act: Kitalys Institute, Spring 2026. www.kitalys.org.

Longevity Dividend: Goldman DP et al. Health Affairs 32(10):1698–1705 (2013); Scott

AJ, Ellison M, Sinclair DA. Nature Aging 1:616–623 (2021).

XPRIZE Healthspan: xprize.org/competitions/healthspan; XPRIZE Milestone 1

announcement, May 2025.